Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:57:21 2024-04-23 am EDT			5-day change	1st Jan Change
91.1 ^CHF	+4.28%		+7.38%	+7.54%

01:51pm	NOVARTIS AG : Barclays keeps a Sell rating	ZD
01:48pm	Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated	MT

NOVARTIS AG : Barclays reaffirms its Sell rating

November 27, 2020 at 07:09 am EST

In a research note published by Emily Field, Barclays advises its customers to Sell the stock. The target price is still set at CHF 75.

Latest news about Novartis AG

NOVARTIS AG : Barclays keeps a Sell rating	07:51am	ZD
Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated	07:48am	MT
European Midday Briefing: Stocks Buoyed by Strong Earnings, FTSE 100 Hits Fresh Record	06:42am	DJ
North American Morning Briefing : Stock Futures Rise, Tesla Earnings in Focus	06:32am	DJ
NOVARTIS : Oddo BHF confirms its recommendation on the share	06:07am	CF
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats	06:01am	RE
NOVARTIS AG : UBS remains its Buy rating	05:35am	ZD
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	05:29am	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	05:12am	MT
NOVARTIS AG : Gets a Buy rating from Jefferies	04:47am	ZD
Novartis Raises Guidance on Profit, Sales Growth -- Update	04:33am	DJ
Novartis raises targets for 2024	03:21am	CF
Techs boost STOXX to one-week high; euro zone data on tap	03:01am	RE
CAC 40: slight upturn in optimism ahead of PMIs	02:38am	CF
Switzerland's Novartis Logs Improved Q1 Net Income, Sales	01:47am	MT
Novartis Raises Guidance on Profit, Sales Growth	01:40am	DJ
EMEA Morning Briefing : Shares Set to Rise as Geopolitical Concerns Ease	12:18am	DJ
Novartis AG Reports Earnings Results for the First Quarter Ended March 31, 2024	10:07pm	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
NOVARTIS AG : UBS reiterates its Buy rating	Apr. 18	ZD
TotalEnergies: shareholders want to separate powers	Apr. 18	CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating	Apr. 18	ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	Apr. 17	MT
Novartis: positive efficacy data in MS	Apr. 17	CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	DJ

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

01:00am - Q1 2024 Earnings Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

95.81 USD

Average target price

105.6 USD

Spread / Average Target

+10.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+7.54%	210B
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+26.67%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ABBVIE INC.	+8.34%	297B
ASTRAZENECA PLC	+6.26%	215B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.79%	149B
AMGEN INC.	-5.59%	146B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Barclays reaffirms its Sell rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals